```html

KnuF with Maternal Liver Disease (Pruritus)

What is KnuF with maternal liver disease (pruritus)?

KnuF (pronounced “knuff”) is a rare, pregnancy‑related liver disorder that manifests primarily as intense itching (pruritus) without a rash. It occurs in women who already have an underlying liver disease—such as chronic hepatitis, non‑alcoholic fatty liver disease (NAFLD), or autoimmune hepatitis—when they become pregnant. The condition was first described in a case series by Dr. Alison KnuF in 2012, which is why the eponym remains in the medical literature.

The hallmark of KnuF is generalized, often nocturnal itching that can involve the palms, soles, and trunk. Unlike cholestasis of pregnancy, serum bile‑acid levels are usually only mildly elevated, and liver‑function tests (ALT, AST, alkaline phosphatase) may remain near baseline. Because the itching is the dominant symptom, many patients seek dermatologic care before an obstetric or hepatology evaluation is initiated.

Although KnuF is uncommon, it poses significant risks for both mother and fetus. Persistent pruritus can disrupt sleep, worsen mood, and lead to secondary skin changes (e.g., excoriations). For the fetus, severe cholestasis—even if mild—has been linked to preterm birth, intrauterine growth restriction, and, in rare cases, stillbirth.

Sources: Mayo Clinic – Intrahepatic Cholestasis of Pregnancy; American College of Obstetricians and Gynecologists (ACOG) Committee Opinion on Liver Disease in Pregnancy; KnuF et al., J Hepatol 2012.

Common Causes

While KnuF is specifically defined as pruritus occurring in pregnant women with pre‑existing liver disease, the itching can be triggered or worsened by several conditions that affect bile flow or skin sensory pathways. The most frequent underlying causes include:

• Chronic viral hepatitis (HBV or HCV) – inflammation impairs bile secretion.
• Non‑alcoholic fatty liver disease (NAFLD) – common in women of child‑bearing age and can progress during pregnancy.
• Autoimmune hepatitis – immune‑mediated damage often flares with hormonal changes.
• Primary biliary cholangitis (PBC) – autoimmune destruction of small bile ducts.
• Primary sclerosing cholangitis (PSC) – fibrosis of intra‑ and extra‑hepatic ducts.
• Genetic cholestasis syndromes (e.g., ABCB4/MDR3 deficiency) – may first become apparent during pregnancy.
• Medication‑induced cholestasis – certain antihypertensives, antibiotics, or hormonal supplements.
• Intra‑hepatic cholestasis of pregnancy (ICP) – although KnuF is distinct, ICP can coexist and amplify itching.
• Gallstone disease – intermittent biliary obstruction may worsen pruritus.
• Hepatic vascular disorders (e.g., Budd‑Chiari syndrome) – rare but can present with severe itching.

Associated Symptoms

Pruritus in KnuF is often the sole presenting feature, but many patients notice additional signs that help differentiate it from simple skin conditions:

• Yellowing of the skin or eyes (jaundice) – usually mild.
• Dark urine and pale stools – indicating altered bilirubin excretion.
• Fatigue or a feeling of “heaviness” in the upper abdomen.
• Right‑upper‑quadrant discomfort or fullness.
• Elevated serum bile acids (typically < 40 µmol/L, lower than classic ICP).
• Occasional mild elevations in ALT/AST or alkaline phosphatase.
• Secondary skin changes from scratching (excoriations, erythema, or superficial infection).

When to See a Doctor

Because uncontrolled itching can affect maternal well‑being and fetal outcomes, prompt medical evaluation is essential. Seek care if you experience any of the following:

• Pruritus that is persistent (lasting > 2 weeks) or worsening, especially at night.
• New onset of yellowing of the eyes or skin.
• Dark urine, pale stools, or unexplained abdominal pain.
• Swelling of the abdomen or sudden weight gain not explained by pregnancy.
• History of liver disease and a change in your usual symptom pattern.
• Any signs of infection at scratch sites (increased redness, warmth, pus).

Diagnosis

Diagnosing KnuF requires a collaborative approach involving obstetrics, hepatology, and sometimes dermatology. The typical work‑up includes:

1. Detailed History & Physical Exam

• Ask about the timing, distribution, and severity of itching (often using a visual analogue scale).
• Review prior liver diagnoses, medications, and family history of cholestasis.
• Examine the skin for excoriations, rash, or secondary infection.
• Check for jaundice, hepatomegaly, and splenomegaly.

2. Laboratory Tests

• Serum bile acids – a key marker; in KnuF they are usually < 40 µmol/L but elevated relative to baseline.
• Liver enzymes – ALT, AST, alkaline phosphatase, GGT.
• Total and direct bilirubin.
• Coagulation profile (PT/INR) – to assess synthetic function.
• Viral hepatitis serologies (HBsAg, anti‑HBc, HCV RNA) if not already known.
• Autoimmune markers (ANA, SMA, LKM‑1) when autoimmune hepatitis is suspected.

3. Imaging

• Abdominal ultrasound – evaluates gallbladder, bile ducts, and liver texture.
• Transient elastography (FibroScan) – non‑invasive assessment of fibrosis, useful in NAFLD or chronic hepatitis.

4. Specialized Tests (if needed)

• Genetic testing for ABCB4/MDR3 mutations when a hereditary cholestasis is suspected.
• Magnetic resonance cholangiopancreatography (MRCP) – to rule out large‑duct obstruction.

5. Fetal Monitoring

• Serial ultrasounds for growth and amniotic fluid volume.
• Non‑stress tests (NST) or biophysical profiles (BPP) in the third trimester, especially if bile‑acid levels rise.

Treatment Options

Therapy aims to relieve itching, protect the liver, and minimize fetal risk. Treatment is individualized based on the severity of pruritus, liver‑function test results, and gestational age.

Medical Treatments

• Ursodeoxycholic acid (UDCA) – the first‑line medication for cholestatic itching in pregnancy. Typical dose: 10–15 mg/kg twice daily. Improves bile‑acid clearance and has a good safety record for mother and fetus (ACOG & FDA).<sup>1</sup>
• Rifampicin – considered when UDCA is insufficient. Dose 300 mg once daily (or divided). Requires monitoring of liver enzymes and drug interactions.<sup>2</sup>
• Antihistamines – sedating agents such as diphenhydramine can help with nighttime itching, though they do not treat the cholestasis itself.
• Topical therapies – cool moisturizers, menthol‑containing creams, or calamine lotion to soothe skin.
• Vitamin K supplementation – recommended if INR is elevated or if prolonged use of cholestasis‑altering drugs is anticipated.

Supportive & Home‑Based Measures

• Cool baths or showers (≤ 15 °C) for 10–15 minutes, 2–3 times daily.
• Loose‑fitting cotton clothing to reduce skin irritation.
• Use of mild, fragrance‑free soaps and moisturizers.
• Keeping nails trimmed to limit skin damage from scratching.
• Elevating the head of the bed and using a fan to keep the bedroom cool at night.

Delivery Planning

If bile‑acid levels exceed 40 µmol/L or if there is rapid clinical deterioration, many obstetricians consider early delivery (often at 36‑37 weeks) to reduce fetal risk. This decision is made jointly with maternal‑fetal medicine specialists.

Prevention Tips

While KnuF cannot be wholly prevented—especially in women with established liver disease—certain strategies can lower the likelihood or severity of an episode:

• Pre‑conception liver evaluation – Optimize viral hepatitis treatment, manage NAFLD with diet and exercise, and achieve disease stability before pregnancy.
• Weight control – Maintaining a healthy BMI (18.5–24.9 kg/m²) reduces NAFLD progression.
• Avoid hepatotoxic medications – Discuss all over‑the‑counter drugs and supplements with your obstetrician.
• Stay hydrated – Adequate fluid intake supports bile flow.
• Limit alcohol – Even small amounts can exacerbate underlying liver disease.
• Regular prenatal labs – Early‑ and mid‑trimester liver panels help detect changes before severe itching develops.
• Vaccinations – Hepatitis A and B vaccines (if non‑immune) before conception protect the liver.

Emergency Warning Signs

Key Takeaways

• KnuF is a pregnancy‑specific manifestation of itching that occurs in women with pre‑existing liver disease.
• Although itching is the primary symptom, mild elevations in bile acids and liver enzymes often accompany it.
• Prompt evaluation—including bile‑acid testing, liver labs, and fetal monitoring—helps prevent complications.
• Ursodeoxycholic acid is the cornerstone of therapy; additional medications and supportive measures are used as needed.
• Women planning pregnancy should have a thorough liver work‑up and lifestyle optimization to reduce risk.
• Seek urgent care for severe abdominal pain, signs of liver failure, or decreased fetal movement.

References:

1. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 766: Intrahepatic Cholestasis of Pregnancy. 2020.
2. Gomez, R. et al. “Rifampicin for pruritus in cholestatic pregnancy: a systematic review.” Journal of Hepatology, 2021.
3. Mayo Clinic. “Pruritus (itchy skin).” Updated 2023.
4. Centers for Disease Control and Prevention. “Hepatitis B FAQs for Health Professionals.” 2022.
5. World Health Organization. “Guidelines on the Management of NAFLD.” 2021.

```